Aldeyra Therapeutics Inc. (ALDX)
undefined
undefined%
At close: undefined
4.90
-0.81%
After-hours Dec 13, 2024, 04:00 PM EST

Company Description

Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases.

The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis.

It also develops ADX-629, a first-in-class orally administered RASP modulator that is Phase II clinical trial for psoriasis, asthma, and COVID-19; and ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of retinitis pigmentosa, as well as for treating primary vitreoretinal lymphoma.

The company has a license agreement with Madrigal Pharmaceuticals, Inc. for developing ADX-1612, which inhibits the protein chaperome for the treatment of inflammatory diseases.

The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014.

Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.

Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc. logo
Country United States
IPO Date May 2, 2014
Industry Biotechnology
Sector Healthcare
Employees 9
CEO Dr. Todd C. Brady M.D., Ph.D.

Contact Details

Address:
131 Hartwell Avenue
Lexington, Massachusetts
United States
Website https://www.aldeyra.com

Stock Details

Ticker Symbol ALDX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001341235
CUSIP Number 01438T106
ISIN Number US01438T1060
Employer ID 00-0000000
SIC Code 2834

Key Executives

Name Position
Dr. Todd C. Brady M.D., Ph.D. Chief Executive Officer, President & Director
David Burke Head of Investor Relations
Dr. Stephen G. Machatha Ph.D. Chief Development Officer
Laura Nichols Operations Manager
Michael Alfieri Principal Financial & Accounting Officer

Latest SEC Filings

Date Type Title
Nov 18, 2024 8-K Current Report
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Nov 07, 2024 10-Q Quarterly Report
Oct 21, 2024 4 Filing
Oct 03, 2024 8-K Current Report
Oct 02, 2024 8-K Current Report
Sep 10, 2024 3 Filing
Sep 03, 2024 8-K Current Report
Aug 14, 2024 4 Filing
Aug 14, 2024 4 Filing